A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
A phase 2/3 trial of Alectinib, Atezolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT03178552 by Hoffmann-La Roche, with 1000 participants planned, started 2017-09-22 and due to reach its primary completion in 2027-06-30. Interventions recorded: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [
Shares Atezolizumab, Roche / Genentech, Pemetrexed, Gemcitabine.
- TrialA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par
Shares Roche / Genentech, Pemetrexed, Cisplatin, Carboplatin.
- TrialA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip
Shares Roche / Genentech, Pemetrexed, Cisplatin, Carboplatin.
- TrialA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Shares Pemetrexed, Gemcitabine, Cisplatin, Carboplatin.
- TrialA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm
Shares Pemetrexed, Gemcitabine, Cisplatin, Carboplatin.
- CompanyChugai Pharmaceutical
Shares Alectinib, Atezolizumab, Roche / Genentech, Non-small-cell lung cancer.
- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.